Sarcoma / 2014 / Article / Tab 1

Research Article

Clinical Features and Outcomes Differ between Skeletal and Extraskeletal Osteosarcoma

Table 1

Characteristics of 4,173 patients with osteosarcoma according to tissue of origin.

CharacteristicSkeletal osteosarcoma ( = 3,917)ESOS () value

Mean age (range)31.4 years*60.7 years**<0.0001
(0–99 years)(9–96 years)
Sex
 Male2,175 (55.5%)117 (45.7%)0.002
 Female1,742 (44.5%)139 (54.3%)
Year of diagnosis
 1973–1979395 (10.1%)9 (3.5%)<0.0001
 1980–1989609 (15.5%)21 (8.2%)
 1990–1999857 (21.9%)64 (25%)
 2000–20092,056 (52.5%)162 (63.3%)
Race
 Caucasian3,031 (77.8%)212 (82.8%)0.232
 African American536 (13.8%)30 (11.7%)
 Asian297 (7.6%)12 (4.7%)
 Native American32 (0.8%)2 (0.8%)
Primary site
 Lower extremity2,392 (62.6%)80 (32.7%)<0.0001
 Upper extremity467 (12.2%)18 (7.3%)
 Head398 (10.4%)18 (7.3%)
 Spine114 (3%)1 (0.4%)
 Ribs/sternum105 (2.8%)0
 Pelvis343 (9%)31 (12.7%)
 Thorax070 (28.6%)
 Abdomen/retroperitoneum027 (11%)
Primary tumor location
 Axial961 (25.1%)154 (61.1%)<0.0001
 Appendicular2,870 (74.9%)98 (38.9%)
Regional lymph node
 Present61 (2.4%)13 (7.7%)<0.0001
 Absent2,519 (97.6%)155 (92.3%)
Stage
 Distant metastasis794 (22.3%)43 (18.6%)0.188
 No distant metastasis2,763 (77.7%)188 (81.4%)
Tumor size
 <10 cm1,252 (63.1%)113 (58.9%)0.241
 ≥10 cm731 (36.9%)79 (41.1%)
Radiation use
 No3,374 (87.7%)186 (74.7%)<0.0001
 Yes473 (12.3%)63 (25.3%)
Histologic type
 Osteosarcoma NOS3,322 (84.8%)239 (93.4%)0.016
 Fibroblastic OS263 (6.7%)10 (3.9%)
 Telangiectatic OS128 (3.3%)3 (1.1%)
 OS in Paget’s79 (2%)0
 Small cell OS30 (0.8%)2 (0.8%)
 Central OS42 (1.1%)1 (0.4%)
 Periosteal OS40 (1%)0
 High grade surface OS13 (0.3%)1 (0.4%)

OS: osteosarcoma; ESOS: extraskeletal osteosarcoma; NOS: not otherwise specified; totals for each variable may vary due to missing data but percentages reflect the represented data.
*Median age is 20 years. **Median age is 64 years.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.